Drug Design and Discovery in Alzheimer’s Disease

www.ebooks.benthamscience.com/book/9781608058228

About the eBook

“Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer’s disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6 and now distributed by Elsevier, the compilation of the 16 articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification, and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of β-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery.

Contents

- Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives
- Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality
- Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease
- Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders
- Multifunctional Enzyme Inhibition for Neuroprotection - A Focus on MAO, NOS, and AChE Inhibitors
- Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease
- Hilbert Transform

For Sales Advertising Inquiries: Contact: marketing@benthamscience.org